A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation
about
Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndromeDrug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNAMultidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseasesMRP3, an organic anion transporter able to transport anti-cancer drugsOverexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myelomaAmplification and expression of the ABC transporters ARA and MRP in a series of multidrug-resistant leukaemia cell sublinesMultidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane VesiclesIdentification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line.Electron-microscopic demonstration of multidrug resistance protein 2 (Mrp2) retrieval from the canalicular membrane in response to hyperosmolarity and lipopolysaccharide.Involvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma.Role of drug transporters and drug accumulation in the temporal acquisition of drug resistanceDifferential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.Usefulness of the MRP2 promoter to overcome the chemoresistance of gastrointestinal and liver tumors by enhancing the expression of the drug transporter OATP1B1Identification of susceptibility loci for colorectal cancer in a genome-wide meta-analysisIdentification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma.Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.Targeted disruption of the PDZK1 gene by homologous recombination.Hepatocellular transport proteins and their role in liver disease.Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma.Suppression of REV7 enhances cisplatin sensitivity in ovarian clear cell carcinoma cells3'-ethynylcytidine, an RNA polymerase inhibitor, combined with cisplatin exhibits a potent synergistic growth-inhibitory effect via Vaults dysfunction.Novel molecular targets for urothelial carcinomaExploring the structure-activity relationships of ABCC2 modulators using a screening approach.Regulation of hepatic ABCC transporters by xenobiotics and in disease states.P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangementLack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines.Epitope mapping of monoclonal antibodies specific for the 190-kDa multidrug resistance protein (MRP).Hepatobiliary transport in health and diseaseA structure-activity relationship study of ABCC2 inhibitors.Expression of gamma-glutamylcysteine synthetase (gamma-GCS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinuAssociations between ABCC2 polymorphisms and cisplatin disposition and efficacyLack of association between expression of MRP2 and early relapse of colorectal cancer in patients receiving FOLFOX-4 chemotherapy.MRP2 (ABCC2, cMOAT) expression in nuclear envelope of primary fallopian tube cancer cells is a new unfavorable prognostic factor.Zuo Jin Wan, a Traditional Chinese Herbal Formula, Reverses P-gp-Mediated MDR In Vitro and In VivoCombination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression.Polymorphic transporters and platinum pharmacodynamicsA perspective on efflux transport proteins in the liverIdentification and bioinformatic characterization of a multidrug resistance associated protein (ABCC) gene in Plasmodium berghei.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.
P2860
Q24540140-7645CF0C-185F-4D50-AEF6-B7FAC45B2F3AQ24564700-E291B02F-E2CF-4430-9159-ABEA368A2CD3Q24601963-EA788627-4063-4F35-905E-F3756679941DQ24650550-B0B02F67-0233-4B00-B136-B85CCBAD2D8BQ24670255-AEABE739-5D70-4849-8AAB-713C7CD3B4CFQ24685860-6F064F28-7757-496B-AE3C-DD914BFB84E9Q28546068-3B80B73B-4831-4CEC-B799-6BC570902C02Q30823476-3660578C-0AF8-403E-BF44-E4BC9057D4EEQ30866906-933B48A1-0293-4B28-8B84-9EB61C5F682AQ32063211-D0D45476-5871-42CB-807F-AB5071B864F0Q33382292-95C428CE-C651-4939-A4CC-762865D7B424Q33523365-773E8C1A-F6D7-47DD-8149-2B9BA37DACB2Q33554403-7AE51067-B778-4B9A-821B-ABDD5E21FBCBQ33798494-DF6F9DC9-B9A0-4160-9862-EEB246F33074Q34048230-C9E17628-C33F-48B1-849F-19BCE02C1384Q34052005-CBFD9586-15DF-47E8-8849-AAC1C966CB6DQ34204238-6C280F0C-DDB7-444D-AFEB-8E24AD0F92B4Q34472849-AAC86FEA-6374-4AD4-A6A3-7DF6A57006F2Q34512014-3DD8334F-AAE7-48D2-9BBA-14E5E3437C1CQ34627891-C7B6628F-D0C8-498D-A569-368B081B72E6Q35051543-A02650B1-DC30-4C9C-8C40-67B00BE57485Q35217985-713D8A54-07D9-4010-AD11-B41370CFFC48Q35527068-1D297C40-5A54-4D3C-AA92-5CF8D53BC3B7Q35620872-31E5A41F-9FE8-42BD-B0D6-21CCAF89E2E8Q35690177-8B8B9955-38BA-4A9E-B950-344504141F24Q35720969-D1D5C0D7-F076-4968-95FF-97FFFD9D4836Q36114681-891F877A-C9AA-4FE3-BA6D-A685736A80B0Q36115145-E06AF9C9-B520-4D38-9879-9748F2020CB5Q36126750-DFBB86CE-76E4-440E-9199-FFFDC4A45558Q36276676-51FA2C24-708F-464F-B16C-8B72388C4061Q36292253-5074944F-A9B2-4DA4-9040-136751E46B14Q36352809-F0FFC034-9FF5-4C3E-8572-2AF21B7D4AEEQ36403439-0BC6BFFE-AC81-41FC-B51A-AFF5EC782477Q36601950-18408B86-96DA-4F02-A705-B15C63BA06F6Q36702964-CC3EAA24-3202-4609-A885-59F5DB1CDC7FQ36982278-25705121-7BAA-44F4-9779-B4FF61E37F91Q36995742-9E0D3059-990F-441D-84D1-5391AEA648B7Q37050337-A3D9213C-2CFB-44D8-B627-A5C1886A9B62Q37073015-BC21AEE0-9DBE-4369-96B7-62384F649839Q37121662-21A58F7F-342C-494B-B8CD-045012761342
P2860
A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation
description
1996 nî lūn-bûn
@nan
1996 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
A human canalicular multispeci ...... th decreased drug accumulation
@ast
A human canalicular multispeci ...... th decreased drug accumulation
@en
A human canalicular multispeci ...... th decreased drug accumulation
@nl
type
label
A human canalicular multispeci ...... th decreased drug accumulation
@ast
A human canalicular multispeci ...... th decreased drug accumulation
@en
A human canalicular multispeci ...... th decreased drug accumulation
@nl
prefLabel
A human canalicular multispeci ...... th decreased drug accumulation
@ast
A human canalicular multispeci ...... th decreased drug accumulation
@en
A human canalicular multispeci ...... th decreased drug accumulation
@nl
P2093
P3181
P1433
P1476
A human canalicular multispeci ...... th decreased drug accumulation
@en
P2093
K Kagotani
K Taniguchi
M Kawakami
T Nakamura
P304
P3181
P407
P577
1996-09-15T00:00:00Z